Results 181 to 190 of about 27,075 (224)

Adaptive Surgical Decision-Making for Synchronous Metastatic Pancreatic Cancer and Early Breast Cancer with a BRCA1 Pathogenic Variant: A Case Report. [PDF]

Surg Case Rep
Akahori T, Yokotani T, Yoshizawa A, Uchiyama T, Yamaguchi R, Sho M.   +5 more
europepmc   +1 more source

ULBP1 is a prognostic biomarker associated with immune suppression in breast cancer. [PDF]

Front Oncol
Mao Q, Zheng Y, Liu S, Li Y, Shen Y, Zhuang H.   +5 more
europepmc   +1 more source

LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations. [PDF]

Mol Cancer Ther
Tran Huynh AM, Lei JT, Brough R, Sallas C, Xu J, Pilcher JB, Gou X, Wang J, Dobrolecki LE, Fandino DM, Berner MJ, Greer A, Song FF, Latka S, Villanueva H, Arimura S, Mao S, Guo Z, Aramburu SI, Chen A, Nguyen T, Gutierrez C, Lopez-Terrada DH, Lim B, Hilsenbeck SG, Lewis MT, Miles G, Mills JC, Echeverria GV, Pettitt SJ, Powell SN, Rosenberg SM, Tutt ANJ, Lord CJ, Ellis MJ, Anurag M.   +35 more
europepmc   +1 more source

Experimental and Mechanistic Validation of PARP1pred for Identifying Potent Leads. [PDF]

Comput Struct Biotechnol J
Chitphuk S, Stitchantrakul W, Wikiniyadhanee R, Dejsuphong D, Kodchakorn K, Lerksuthirat T.   +5 more
europepmc   +1 more source

RAD21 regulation of the enhancer-promoter chromatin loop of RAD51 promotes PARPi resistance in ovarian cancer. [PDF]

J Transl Med
Gou R, Chang X, Cheng H, Ye X, Liu O, Hu Y, Lin B, Li X.   +7 more
europepmc   +1 more source

Functional and omics-based rationale for the induction of BRCAness by androgen receptor pathway inhibitors to sensitize prostate cancer to PARP inhibition, regardless of HRR status. [PDF]

Br J Cancer
Elsesy ME, Moustafa A, Oh-Hohenhorst SJ, Müller C, Alawi M, Mair T, Siebels B, Hu Z, Hahn J, Burdak-Rothkamm S, Tilki D, Schlüter H, Petersen C, Maurer T, von Amsberg G, Bokemeyer C, Rothkamm K, Mansour WY.   +17 more
europepmc   +1 more source

Phase II study of olaparib plus durvalumab in EGFR-mutant NSCLC transformed to small cell lung cancer. [PDF]

Oncologist
Mohindroo C, Takahashi N, Nichols S, Pinkiert D, Thomas A.   +4 more
europepmc   +1 more source

Use of Rucaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma: A Case Report From a Tertiary Centre in India. [PDF]

Cureus
Arora A, Rastogi S, Tilak A, Ahmed S, Rathore R.   +4 more
europepmc   +1 more source

PARP1 rewires neuroinflammatory and redox metabolism associated with reactive neuroglia in neuropathic pain. [PDF]

Redox Biol
Denaro S, D'Aprile S, Gervasi A, Russo V, Bellia F, Giallongo S, Lavoro A, Candido S, Braga A, Gourine AV, Li Volti G, Pasquinucci L, Amorini AM, Parenti C, Parenti R, Vicario N.   +15 more
europepmc   +1 more source

Tumor cell intrinsic dsRNA innate immune response triggered by PARP inhibitor is compromised in BRCA1-deficient breast cancer by repressing IRF3. [PDF]

Protein Cell
Zhang C, Zhou JB, Lei JH, Ang IL, Miao K, Xu X, Poon TCW, Cheung E, Deng CX.   +8 more
europepmc   +1 more source